Rise and shine, everyone. Another day is upon us. The short people are at the schoolhouse and the official Pharmalot mascots are eyeing squirrels on the corporate campus. What about you? Eyeing anything interesting? Maybe those notes for the next meeting? For now, you can peek at the news of the world. Hope your day goes well and see you soon...
Dendreon Signs Glaxo To Supply Provenge Antigen (Reuters)
AstraZeneca Urges 20 Percent More FDA Funding (PharmaTimes)
Dey Pharma Pays Wisconsin $2M To Settle Fraud Charge (Becker's ASCReview)
Lilly And Parexel Sign Asia-Pacific Development Deal (Outsourcing Pharma)
Ranbaxy Has Exclusive Right To Sell Generic Aricept (Bloomberg News)
EU Meets To Decide Avandia Fate (Reuters)
Merck Expands Deal With NicOx (Zenopa)
FDA Panel Backs Boehringer Stroke Drug (Reuters)
Genzyme's Synvisc Is Approved In Japan (Associated Press)
Bristol Exec: European Pricing Pressures Are Mounting (Dow Jones)
Fast-Tracking Proof-Of-Concept Trials (R&D Directions)
Abbott Is Pharma's Big Dealmaker (The Deal)
our squirrel courtesy of gilles gonthier on flickr
1 Comment
For orthopedic patients possibly requiring Synvisc, here's a warning. Don't get ripped off by greedy orthopaedic surgeons who will tell you that you need three office visits over six months for three injections of Synvisc. That is the OLD product. The new Genzyme product is longer lasting, only requiring a single injection over a six month period.